Brandon Dawson: Why Abu Dhabi Is Ground Zero For His Next Big Build

There is no shortage of health data today. A smartwatch can tell you how well you slept. A blood test can produce pages of biomarkers. Genetic testing can reveal predispositions that would have been inaccessible to the average consumer a generation ago. Apps can track heart rate, glucose, activity, stress, recovery and nutrition.

And yet, Brandon Dawson believes one of the biggest problems in modern health remains surprisingly basic: people have more information about themselves than ever before, but often have little idea what to do with it.

That problem sits at the center of Dawson’s push into precision health through 10XREVIV, a partnership between Abu Dhabi-based global health company M42, US-based human optimization and lifespan company 10X Health, and UK-headquartered precision-nutrition company REVIV Global – and its new precision-health platform MYiOX Health. 

The vision to turn a fragmented system into a connected, functioning precision-health ecosystem draws on Dawson’s extensive experience helping organizations unlock their potential and building the infrastructure needed to scale.

That business acumen has been shaped by more than three decades of building, scaling and exiting companies. Dawson founded Sonus, a Warburg Pincus-backed consolidation company that he took public on the American Stock Exchange at age 29, before founding Audigy Group, which he bootstrapped and later sold for US$151 million in 2016. He subsequently helped the acquiring public company grow its share price from US$18 to US$94 within three years, adding US$3.5 billion in market value. Today, Dawson is the co-founder, Chairman, CEO, and Managing Partner of 10X Health and Cardone Ventures, a business growth and investment firm that he co-founded with his wife Natalie Dawson and American entrepreneur and real estate investor Grant Cardone. 

Pointing out that Cardone Ventures has invested US$45 million through convertible loans into REVIV Global and partnered with the company in 10XREVIV to co-create MYiOX Health, Dawson explains that he is now applying the wisdom gained from building and scaling businesses across multiple sectors to bring together the best of all three companies in advancing precision nutrition, longevity, and precision healthcare focused on extending both lifespan and healthspan.

“The biggest opportunities are often not created by inventing one more product,” Dawson says. “They’re created by connecting things that already exist but do not work together.” 

It is through that lens that Dawson sees the healthspan, wellness, and longevity sector. 

Consumers are surrounded by diagnostics, wearables, supplements, nutrition programs and increasingly sophisticated medical options. At the same time, longevity clinics are proliferating, physicians are moving into preventive and personalized medicine, and interest in understanding individual biology continues to grow. 

The opportunity, Dawson believes, is not simply to add another company to that crowded landscape. It is to create the infrastructure connecting it. That is the idea behind MYiOX Health, the world’s first global operator in 40 countries.

From Data to Decision

Dawson describes MYiOX as an end-to-end human optimization platform designed to take an individual’s biological information and translate it into personalized actions—then connect those actions, where appropriate, to qualified clinical care globally. Providing consistency and continuity for individual care. 

The ambition is significant. 

Instead of producing another score or dashboard for consumers to interpret themselves, MYiOX is intended to create a continuous journey: collect data, understand it, make recommendations, act on those recommendations, measure the results, and use the new information to inform what happens next on a global basis.

At the intelligence layer sits what the company describes as its BEAM Score, being developed around hundreds of life-science-weighted biomarkers. The larger objective, however, is not the score itself. “Giving somebody another score isn’t enough,” Dawson says. “Information without action doesn’t optimize anything.” 

The platform is being designed to translate biological intelligence into recommendations spanning nutrition, lifestyle, protocols, products and supplements, while providing a pathway toward clinical intervention when that becomes appropriate. 

The distinguishing idea is measurement. 

Dawson does not only want the platform to tell an individual what they could change. He wants it to determine what happened after they changed it. Biological data informs an intervention. The intervention produces an outcome. That outcome creates more data. The cycle begins again. 

In technology language, it is a feedback loop. In health terms, Dawson sees it as an attempt to make personalization dynamic rather than static.

Building the Pieces

MYiOX did not emerge in isolation. 

Dawson points to the work already carried out through 10X Health, REVIV and the subsequently combined 10X REVIV platform as the foundation from which the larger MYiOX vision is being developed. 

Through 10X Health, Dawson says his team gained direct insight into what health-conscious consumers increasingly want: not simply access to information, but help understanding what their information means. 

“Understand me, show me my data, and tell me what I can actually do with it,” is how Dawson summarizes that demand. 

REVIV, meanwhile, brings an established international clinical and life-sciences infrastructure. Its founder and CEO, Sarah Lomas, built the Manchester-headquartered med-tech company around a vision of making elective IV therapies, vitamin supplementation, hydration and preventative healthcare more widely accessible. Today, REVIV operates a clinical network spanning more than 40 countries, supported by a common clinical SaaS platform designed to accommodate local healthcare regulations.

Over more than a decade, Lomas and her team have expanded that foundation beyond IV therapy into precision nutrition and genetic analysis, investing in the science and technology required to connect individual genetic profiles with nutritional and health outcomes. That work has become particularly important to MYiOX: Dawson describes the life-sciences expertise developed by Lomas and her team at REVIV as the “human intelligence” behind the platform and a key reason for investing in the company.​​

The plan is to bring these layers together. 

The consumer-facing experience and the clinical infrastructure are intended to communicate through a common technology architecture, with biological information moving through a proprietary life-sciences framework before being translated into an individualized plan. 

Dawson characterizes MYiOX not as a startup idea developed during the most recent longevity boom, but as the convergence of years of work across healthcare, science, technology and business building.  “This isn’t an idea we woke up with six months ago,” he says. “It’s the convergence of years of science, healthcare, technology, consumer experience and business building.” 

For an entrepreneur whose career has largely revolved around creating and scaling businesses, that distinction matters. MYiOX is not being positioned simply as a health company. Dawson is trying to build a global health and lifespan platform.

Optimize First

There is also a personal philosophy behind the business. Dawson and his wife Natalie, together with their partners the Cardone family, have framed their mission around helping people better understand their individual biology and giving them evidence-based tools to improve it. 

That philosophy requires careful language, particularly when the discussion reaches medication. 

Dawson is explicit that the objective is not to encourage people to stop prescribed medication. Rather, the company’s stated aim is to give individuals and their healthcare professionals better information and additional evidence-based nutrition and lifestyle options that may, when clinically appropriate, help reduce unnecessary dependence on medication

Clinical decisions, he stresses, remain with qualified medical professionals. Precision nutrition consequently becomes one of the most scalable entry points. Unlike a medical procedure performed occasionally, nutrition touches almost everyone every day. The group’s 10X Precision Nutrition System is being positioned around genetic insights, blood biomarkers, mitochondria function, and nutritional science to make that everyday interaction more individualized. 

It also illustrates a much larger principle underlying MYiOX. If two people are biologically different, Dawson argues, why should their health strategies automatically be identical?

Your Biology Should Travel With You

For Dawson, personalization should not disappear when someone gets on an airplane. 

A person living between Abu Dhabi, Miami and London may currently deal with multiple physicians, apps, laboratories, wellness providers and clinics, each possessing only a fragment of that person’s health information. 

MYiOX is being designed around a different premise. “Your biology should travel with you,” Dawson says. “Your health strategy shouldn’t reset every time you cross a border.” 

Through a shared clinical and technology infrastructure, the goal is eventually to allow an individual’s biological profile and personalized protocol to move across participating markets rather than forcing them to effectively begin again with every new provider. 

That same continuity is intended to address another fracture in modern healthcare: the divide between being a consumer and becoming a patient. 

Most wellness technology exists outside traditional clinical systems. A person can spend months tracking sleep, exercise, nutrition and biomarkers through consumer platforms, but the moment medical intervention becomes necessary, that information often sits outside the healthcare environment they enter. 

Dawson wants MYiOX to bridge that wall. The platform is being designed to connect biological understanding and wellness recommendations with trained clinical environments and qualified healthcare professionals when medical care becomes necessary. 

“Most health platforms stop at information,” Dawson says. MYiOX, by contrast, is intended to connect information to action, action to care, and care back to measurable biological outcomes, without giving medical recommendations. But rather insights and information to act on in real time. 

Why Abu Dhabi?

For a platform being conceived as global from the beginning, Dawson faced a strategic question. 

Where should it make its debut? Based on the advice of his mentor, Michael Milken, Chairman of the Milken Institute, his answer was Abu Dhabi. The choice, he says, extends well beyond access to investment.

Dawson points to the late Sheikh Zayed bin Sultan Al Nahyan’s emphasis on human development as one of the philosophies that connected him personally to the emirate. 

He sees a modern continuation of that philosophy in Abu Dhabi’s investments in genomics, population health, artificial intelligence, precision medicine and life sciences. “The investments are different because the world is different,” Dawson says. “But to me, the underlying philosophy is remarkably consistent: invest in the individual, invest in their health, invest in their knowledge and capabilities, and you invest in the future of the country.”

RELATED: Beyond Capital: Why Foreign Startups Are Building Their Next Chapter in Abu Dhabi

It is difficult to ignore the fit. Abu Dhabi has spent years positioning itself as a leader in healthcare, biotechnology and longevity as strategic sectors. For a company trying to build around individualized biology, Dawson is equally drawn to the UAE’s diversity. The country brings together more than 200 nationalities, according to the source material, offering the kind of multicultural environment Dawson believes is important for a health platform whose core thesis begins with human biological individuality. 

For Dawson, Abu Dhabi represents the intersection of long-term capital, government ambition, scientific infrastructure, healthcare capability and international talent. 

And that brings him to M42.

A Strategic Alignment With M42

Dawson describes MYiOX’s relationship with Abu Dhabi-headquartered health company M42 as a strategically important part of the broader story. 

M42 facilitates the Emirati Genome Programme, which the source material says has attracted approximately 780,000 UAE national participants, and has worked with organizations including Microsoft and the Broad Institute of MIT and Harvard on areas related to genomic and precision-health infrastructure. 

For Dawson, the significance is less about individual partnerships than the ecosystem they represent. Abu Dhabi is not merely accumulating genomic information. Its health sector is working toward integrating genomics with clinical decision-making, biobanking, prevention, precision medicine and healthy longevity. 

That alignment is exactly what Dawson says he was looking for. “I didn’t want MYiOX to launch somewhere simply because there was capital,” he says. “I wanted to be where leadership, culture, science, healthcare and long-term investment were aligned around human potential.”
This is why he chose Abu Dhabi, and today, 10X REVIV is a proud Masdar City entity, where Dawson intends to tap into the emirate’s AI infrastructure and talent to advance the company’s mission globally.

The Business Builder’s Bet

Strip away the biomarkers, genetics and clinical terminology and Dawson’s strategy begins to resemble something familiar from other industries transformed by technology. Platforms tend to win not because they manufacture every individual component of an ecosystem, but because they create the infrastructure that allows those components—and their users—to interact. 

Dawson has spent more than two decades thinking about businesses through precisely that lens. He has operated as founder, investor, buyer, seller and business builder. One lesson he says has followed him throughout that career is that some of the largest enterprise-value opportunities can arise from creating the infrastructure through which an entire ecosystem operates. 

That is ultimately how he sees MYiOX. “We’re not trying to build another supplement company. We’re not trying to build another wearable. We’re not trying to build another longevity clinic. And we’re not trying to build another health-data dashboard,” he says. 

“We’re building the platform that connects them.” 

Its proposed architecture brings together a consumer application, biological intelligence, personalized recommendations, precision nutrition, future marketplace capabilities, clinical connectivity and MYiOX Pro, the company’s clinical SaaS layer. If that architecture develops as Dawson intends, it gives MYiOX two potential audiences simultaneously. On one side sits the individual trying to better understand and optimize their health. On the other sits the healthcare professional helping them do it. “That’s how you move from building a product to building a platform,” Dawson says, “and from building a platform to building an ecosystem.”

The October Moment

The MYiOX brand will be unveiled in October at the Abu Dhabi Future Health Summit, with the platform launching in January, 2027. 

After years of scientific development, technology investment, consumer-health experience and clinical infrastructure building, Dawson and his partners are preparing to unveil the MYiOX Health global platform in Abu Dhabi.

For a businessman accustomed to thinking in terms of enterprise value, however, this project represents something broader than the next transaction. The thesis behind it is remarkably simple. No two people are biologically identical. Therefore, Dawson argues, the future of health cannot remain entirely one-size-fits-all. 

The real opportunity is not to produce more data for people already overwhelmed by data. It is to help them understand their biology, decide what to do with that understanding, connect them with appropriate clinical care when it becomes necessary, and then determine whether those decisions actually produced results. 

For Dawson, this may be the ultimate evolution of the business-building philosophy that has defined much of his career. He has spent decades building companies. Now he wants to build an ecosystem around something considerably more personal. “This next chapter is about bringing business building, technology, life sciences, nutrition and medicine together around the most important asset any of us will ever own,” Dawson says, “Ourselves.”

RELATED: Captain Pradeep Singh on Dubai Becoming a Global Hub for Intellectual Capital